Faeth Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 1 month.
- Its last 3 Sell calls were actually followed by a +45% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -43.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 10.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -74.0% | Better than 7% |
| Return on invested capital | -71.5% | Better than 4% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -75.4% | Better than 1% |
| 6-month return | -55.7% | Better than 6% |
| 12-month return (ex latest month) | 95.8% | Better than 95% |
| Distance below 52-week high | 81.3% | Better than 2% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.1x | Better than 86% |
| Debt to assets | 6.6% | Better than 76% |
| Interest coverage | -657.9x | Better than 2% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 633.2% | Better than 100% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 8.69
- Open
- 8.52
- Day range
- 7.84 - 9.13
- Avg price
- 8.26
- Volume
- 419.11K
- Turnover
- 3.46M
- Turnover ratei
- 2.48%
- Volume ratioi
- 0.62
- Amplitudei
- 14.87%
- 52-week rangei
- 7.45 - 42.14
Valuation
- P/Ei
- -0.47
- P/E (TTM)i
- -0.35
- P/Bi
- 1.26
- EPSi
- -16.72
- Book value / shi
- 6.23
- Net profit
- -432.11M
- Net assets
- 161.09M
Share structure
- Market cap
- 203.65M
- Float capi
- 132.95M
- Shares out
- 25.84M
- Float sharesi
- 16.87M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-02-04
81.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+9.14K net over the window
Short interest
- Shares short
- 2.73M
- % of floati
- 10.57%
- Days to coveri
- 6.31
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Faeth Therapeutics (FTH)?
Faeth Therapeutics last traded at 7.88. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Faeth Therapeutics's market cap?
About 203.65M.
What is the P/E ratio of Faeth Therapeutics?
The trailing twelve-month P/E is -0.35. The Valuation tab shows it against the stock's own five-year range.
Does Faeth Therapeutics pay a dividend?
Faeth Therapeutics does not currently pay a regular dividend.
Is Faeth Therapeutics a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 57.78, which implies 633.2% upside from the current price. This is not investment advice.
What is Faeth Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Faeth Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Faeth Therapeutics discussion 0 comments